Fulcrum Therapeutics, Inc. (FULC) Balance Sheet
As of 2026-06-30 (10-Q), Fulcrum Therapeutics, Inc. (FULC) reported total assets of $324.0M, total liabilities of $13.3M and shareholders' equity of $310.7M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $48.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
FULCFulcrum Therapeutics, Inc.Follow FULC — free
—
Price chart with a free account
- Market cap
- 280.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 96.7 | 57.1 | 35.4 | 35.1 | 25.6 | 58.2 | 197.5 | 48.5 | |
| Short-term investments | 0.0 | — | — | — | — | — | — | — | |
| Current assets | 100.1 | 119.5 | 226.0 | 207.5 | 242.2 | 249.9 | 357.5 | 322.9 | |
| Total assets | 110.4 | 129.6 | 235.0 | 226.7 | 257.7 | 260.7 | 366.3 | 324.0 | |
| Current liabilities | 12.1 | 26.7 | 19.2 | 16.7 | 13.7 | 11.0 | 13.0 | 10.3 | |
| Total liabilities | 23.3 | 34.4 | 23.5 | 27.7 | 22.5 | 17.7 | 17.3 | 13.3 | |
| Shareholders' equity | 87.2 | 95.2 | 211.5 | 198.9 | 235.2 | 243.0 | 349.0 | 310.7 |
USD millions · SEC XBRL
Fulcrum Therapeutics, Inc. — questions
- How much cash does Fulcrum Therapeutics, Inc. have?
- $48.5M in cash and cash equivalents as of 2026-06-30.
- What are Fulcrum Therapeutics, Inc.'s total assets?
- $324.0M as of 2026-06-30.
- What is Fulcrum Therapeutics, Inc.'s shareholders' equity?
- $310.7M as of 2026-06-30.
Every figure on this page comes from Fulcrum Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.